Waltham, MA, United States of America

Letian Kuai

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2017-2018

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Letian Kuai in Therapeutic Development

Introduction

Letian Kuai, an inventive mind based in Waltham, MA, has made significant strides in the fields of affinity chromatography and therapeutic agent development. With two patents to his name, Kuai’s work emphasizes advancing medical and pharmaceutical applications that can enhance therapeutic efficacy.

Latest Patents

Kuai's latest patents focus on "Compounds for Affinity Chromatography and for Extending the Half-Life of a Therapeutic Agent." These compounds are particularly useful in the purification of serum albumin, especially human serum albumin (HSA) and its fusion proteins. Furthermore, his methods for extending the half-life of therapeutic agents highlight the conjugation of these innovative compounds to therapeutic peptides or small molecules. This approach allows for binding to HSA and promotes prolonged release of therapeutic agents, which is crucial for improving patient outcomes.

Career Highlights

Letian Kuai currently works at GlaxoSmithKline Intellectual Property Development Limited, where he utilizes his expertise to push the boundaries of pharmaceutical innovation. His contributions stem not only from his individual patents but also from the collaborative environment in which he operates, where the intersections of chemistry and medicine are explored.

Collaborations

In his career, Kuai has collaborated with notable colleagues such as Peter Kumpalume and Oliver Schon. These partnerships foster a dynamic exchange of ideas and expertise, enabling them to tackle complex challenges in therapeutic development and patenting innovative solutions.

Conclusion

Letian Kuai's work in the field of therapeutic agents and affinity chromatography is paving the way for advancements that could significantly impact the pharmaceutical industry. His dedication to innovation and collaboration at GlaxoSmithKline Intellectual Property Development Limited stands as a testament to the potential of scientific inquiry in improving medical treatments and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…